222 related articles for article (PubMed ID: 20336161)
1. Pituitary gland: can prolactinomas be cured medically?
Molitch ME
Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
Miki N
Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
[No Abstract] [Full Text] [Related]
3. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
4. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
5. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.
Pereira AM
Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709
[TBL] [Abstract][Full Text] [Related]
6. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
7. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
McCall D; Hunter SJ; Cooke RS; Herron B; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 2007 Jan; 66(1):149-50. PubMed ID: 17201816
[No Abstract] [Full Text] [Related]
8. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.
Dekkers OM; Lagro J; Burman P; Jørgensen JO; Romijn JA; Pereira AM
J Clin Endocrinol Metab; 2010 Jan; 95(1):43-51. PubMed ID: 19880787
[TBL] [Abstract][Full Text] [Related]
9. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
Oguz A; Tuzun D; Sahin M; Gul K
Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
11. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited.
Sosa-Eroza E; Espinosa-Cárdenas E
Arch Med Res; 2023 Dec; 54(8):102893. PubMed ID: 37806785
[TBL] [Abstract][Full Text] [Related]
12. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
13. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
14. Pituitary apoplexy associated with cabergoline therapy.
Chng E; Dalan R
J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
[TBL] [Abstract][Full Text] [Related]
15. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
Delgrange E; Donckier J
J Clin Endocrinol Metab; 1997 Aug; 82(8):2755-6. PubMed ID: 9253367
[No Abstract] [Full Text] [Related]
16. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
17. Prolactinomas.
Couldwell WT; Weiss MH; Laws ER
N Engl J Med; 2004 Mar; 350(10):1054-7; author reply 1054-7. PubMed ID: 15002121
[No Abstract] [Full Text] [Related]
18. Cabergoline and quinagolide therapy for prolactinomas.
Webster J
Clin Endocrinol (Oxf); 2000 Nov; 53(5):549-50. PubMed ID: 11106914
[No Abstract] [Full Text] [Related]
19. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
20. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?
Klibanski A
J Clin Endocrinol Metab; 2009 Jul; 94(7):2247-9. PubMed ID: 19584197
[No Abstract] [Full Text] [Related]
[Next] [New Search]
